A Randomized, 2-Arm, Open-Label, Ph-II Study of Abemaciclib Combined With ET w/ or w/o CT With Paclitaxel as 1L in Patients With Unresectable Locally Advanced or Metastatic HR(+)/HER2(-) BC With Aggressive Disease Criteria
Latest Information Update: 08 Aug 2024
At a glance
- Drugs Abemaciclib (Primary) ; Fulvestrant (Primary) ; Letrozole (Primary) ; Antineoplastics; Gonadotropin releasing hormone modulators; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms ABIGAIL
- 28 Feb 2024 Planned End Date changed from 1 May 2024 to 30 Jun 2025.
- 28 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jun 2024.
- 15 Jan 2024 Status changed from recruiting to active, no longer recruiting.